Currently Viewing:
Newsroom
Currently Reading
What We're Reading: Cheaper Hepatitis C Drugs; Pharma Discount Rollback; HHS Pulls Fetal Tissue Research
September 25, 2018 – AJMC Staff
Gottlieb Proposes Payment Incentives to Spur Development of AMR Therapies
September 17, 2018 – Allison Inserro
Keytruda Earns Priority Review as Monotherapy in NSCLC
September 17, 2018 – Samantha DiGrande
What We're Reading: Lawsuit Over Short-Term Insurance; Panel Worried About Arkansas; Heroin Use Drops
September 17, 2018 – AJMC Staff
Citing Teen Vaping Epidemic, FDA Puts 5 e-Cigarette Makers on 60-Day Notice
September 12, 2018 – Allison Inserro
Hospital Groups Sue HHS Over Delayed Implementation of 340B Ceiling Prices, Penalties for Overcharging
September 12, 2018 – Jaime Rosenberg
Review Outlines Glatopa's FDA Approval to Treat MS
September 10, 2018 – Alison Rodriguez
What We're Reading: FDA Recruiting; Azar Meets With Lawmakers; Kavanaugh Emails
September 07, 2018 – AJMC Staff
Pembrolizumab Gets Priority Review for Merkel Cell Carcinoma
September 04, 2018 – Mary Caffrey

What We're Reading: Cheaper Hepatitis C Drugs; Pharma Discount Rollback; HHS Pulls Fetal Tissue Research

AJMC Staff
Gilead Sciences will sell authorized generics of its blockbuster hepatitis C drugs Epclusa and Harvoni; the pharmaceutical industry inserted a measure into an opioid bill to reverse discounts they would be required to give next year to seniors enrolled in Medicare Part D plans; the Trump administration has terminated a contract with a fetal tissue firm after being criticized by antiabortion groups and Republican lawmakers.

Gilead Sciences to Sell Authorized Generics of Hepatitis C Drugs

Gilead Sciences will sell authorized generics of its blockbuster hepatitis C drugs Epclusa and Harvoni, Bloomberg reported. The brand-name versions sparked widespread debate about US pharmaceutical costs when they were introduced at a price of more than $1000 per pill. The less expensive versions will cost $24,000 for a course of treatment, which compares with a list price for Harvoni of $94,500. The company’s hepatitis C drugs remain among the best-selling pharmaceutical products in history, but they've also made Gilead the subject of congressional hearings and accusations of greed.

 

Pharma Industry Seeks to Reverse Planned Increase in Medicare Drug Discounts 

The pharmaceutical industry inserted a measure into an opioid bill to reverse discounts they would be required to give next year to seniors enrolled in Medicare Part D plans, The New York Times reported. The $4 billion giveback is encountering fierce opposition. The Pharmaceutical Research and Manufacturers of America, or PhRMA, is calling the measure a “technical correction” to a bipartisan budget law signed by President Donald Trump in February. The law required drug manufacturers to provide deeper discounts to Medicare beneficiaries whose spending on prescription drugs falls within the coverage gap. The 50% discount on brand-name drugs is set to rise 70% next year.

 

HHS Cancels Fetal Tissue Research Contract 

The Trump administration has terminated a contract with a fetal tissue firm after being criticized by antiabortion groups and Republican lawmakers, The Hill reported. The FDA had contracted with Advanced Bioscience Resources for $16,000 to acquire fetal tissue to implant into mice for research purposes. HHS ended the contract because it was not "sufficiently assured" that the contract included appropriate protections and followed requirements for fetal tissue research. Supporters of fetal tissue research say it has led to the development of medical advances, including the polio vaccine. HHS said it is also conducting an audit of all acquisitions involving human fetal tissue.

Related Articles

Coverage for Hepatitis C Drugs in Medicare Part D
Gilead Again Defends Against Lawsuits Over Patents for Hepatitis C Treatments
Treating Medicaid Patients With Hepatitis C: Clinical and Economic Impact
Reducing Out-of-Pocket Cost Barriers to Specialty Drug Use Under Medicare Part D
Diversity Seen in How Medicare Part D Plans Add New Drugs
 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up